US FDA issues draft guidance on developing drugs for neglected tropical diseases
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has issued a draft guidance to assist manufacturers in the clinical development of drugs for treating or preventing neglected tropical diseases of the developing world, such as malaria, dengue hemorrhagic fever, leishmaniasis and human African trypanosomiasis1.